Steatosis in Cirrhosis: A Prognostic Marker for Liver‐Related Outcomes in Metabolic‐Dysfunction Associated Steatotic Liver Disease
- 30 July 2026
- journal article
- Published by Wiley in Liver International
- Vol. 46 (9)
Abstract
Background and Aims: The predictive ability of histological components in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) has not been well studied. Here, we look at the ability of digital pathology through the components of qFIBs (qfibrosis, qInflammation, qBallooning, qSteatosis) in predicting the risk of Major Adverse Liver Outcomes (MALO). Method: 235 liver biopsy images were retrieved, and the composite end point of MALO, including overall death, hepatic encephalopathy (HE), ascites, variceal haemorrhage and hepatocellular carcinoma (HCC), was studied in parallel with the Non‐alcoholic Steatohepatitis Clinical Research Network (NASH‐CRN) score and qFIBs. Results: The predictive power of qFibrosis for MALOs (qF3/4 vs. qF0/1/2, HR 6.64, 95% CI 1.69–26.06, log rank p ‐value 0.001) was comparable to NASH‐CRN (F3/4 vs. F0/1/2, HR 7.02, 95% CI 2.37–20.84, log rank p ‐value < 0.001). Interestingly, a lower steatosis grade, rather than being a protective factor, correlated with poorer outcomes for both the qFIBs (qS0/1 vs. qS2/3 HR 17.24, 95% CI 3.12–95.32, log rank p value < 0.001) and NASH‐CRN (S0/1 vs. S2/3 HR 6.30, 95% CI 2.14–18.61, log rank p value < 0.001). Lower qSteatosis scores of qS1 and below among the cirrhotic group ( n = 35) also showed a six‐fold higher risk of MALOs (< 1.50 vs. ≥ 1.50, HR 6.40, 95% CI 1.08–37.92, log rank p value < 0.011), likely due to the reduction of steatosis in the cachectic state of a patient with end stage liver disease. Samples with lower percentages of macro‐vesicular vacuoles had a fourfold increased risk of MALOs (HR 4.41, 95% CI 1.06–18.43, log rank p value 0.017). Conclusion: Lower steatosis grades in higher fibrosis stages correlate significantly with the occurrence of MALO. Our findings instigate exploration of the process of fat resorption in MASLD and its relation to outcomes.Keywords
This publication has 20 references indexed in Scilit:
- The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trialsJournal of Hepatology, 2025
- Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASHJournal of Hepatology, 2022
- qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic SteatohepatitisHepatology, 2019
- The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsJournal of Hepatology, 2018
- Dual‐photon microscopy‐based quantitation of fibrosis‐related parameters (q‐FP) to model disease progression in steatohepatitisHepatology, 2017
- Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?Hepatology, 2012
- Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver diseaseJournal of Hepatology, 2008
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver diseasePowell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years [Hepatology 1990; 11:74–80]Journal of Hepatology, 2004
- The Natural History of Nonalcoholic Steatohepatitis: A Follow–Up Study of Forty–Two Patients for Up to 21 YearsHepatology, 1990